Nuvaring (Ethinylestradiol, Etonogestrel)

NuvaRing, a combined estrogen‑progestogen contraceptive, is used in hormonal regulation to prevent pregnancy.

• Prevention of pregnancy: provides reliable, reversible birth control for women of reproductive age.

• NuvaRing releases ethynylestradiol and etonogestrel directly into the vaginal mucosa, where the estrogen component stabilizes the endometrial lining and the progestogen component suppresses the hypothalamic‑pituitary‑gonadal axis. This dual action prevents the mid‑cycle surge of luteinizing hormone, thereby inhibiting ovulation, while also thickening cervical mucus and inducing endometrial changes that reduce the likelihood of implantation.

NuvaRing may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Vaginal irritation or discharge: mild irritation, itching, or increased discharge at the site of insertion.
• Headache: transient headaches of mild to moderate intensity.
• Nausea: occasional stomach upset or feeling of nausea.
• Breast tenderness: mild swelling or tenderness of the breasts.
• Irregular bleeding: spotting or breakthrough bleeding between cycles.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis, pulmonary embolism, or stroke.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Hepatic adenoma: benign liver tumor, rarely reported.

When prescribing NuvaRing, clinicians should consider several safety precautions to minimize risks.

• Contraindicated in pregnancy: product is classified as pregnancy category X and must not be used by pregnant women.
• Avoid in smokers over 35 years: increased risk of cardiovascular events.
• Screen for thromboembolic history: do not use in women with a history of clotting disorders.
• Monitor blood pressure: hormonal contraceptives may elevate blood pressure.
• Assess liver function: severe hepatic disease may affect hormone metabolism.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

NuvaRing can interact with other medicines that alter hormone metabolism or affect its efficacy.

Major Interactions (Avoid)

• Enzyme inducers (e.g., rifampin, phenytoin, carbamazepine, St. John’s wort): significantly reduce hormone levels, risking contraceptive failure.
• Protease inhibitors (e.g., ritonavir): may lower contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., ketoconazole, itraconazole): may increase hormone concentrations, heightening side‑effect risk.
• Selective serotonin reuptake inhibitors (e.g., fluoxetine): may slightly increase bleeding tendency.
• Certain antibiotics (e.g., tetracycline): may modestly reduce contraceptive efficacy.